Cytek Biosciences, Inc.
Health
Performance
7.0
Risk
Sell
Buy
Curious about the Scores? Learn more.

Cytek Biosciences, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

16.07.2026
Slight bounce. Could be noise – or a comeback brewing.
16.07.2026
Danger zone. Balance sheet’s flashing red across the board.
27.06.2026
Breaking down. The red game over screen is flashing.
24.06.2026
Off life support. Still risky, but slightly less scary.
CTKB
Cytek Biosciences, Inc.
4.57
-0.22%
7.0
Sell
Buy
Cytek Biosciences, Inc.

Cytek Biosciences, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Cytek Biosciences, Inc. do? Business model and key facts

Get the full picture of Cytek Biosciences, Inc.: what it builds, where it operates, and how it makes money.

Cytek Biosciences, Inc. Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 663

Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.

shop
Company facts
Wenbin Jiang
CEO
663
Employees worldwide
shop
Performance
47.42%
Last 12 months
-75.64%
Last 5 years
shop
Growth
$201.49M
Revenue year
$-66,539,000
Net income
shop
Valuation
$596.64M
Market Cap
-9.71
Price/Earnings Ratio

Stocks related to Cytek Biosciences, Inc.

Selected based on industry alignment and relative market positioning.

SRDX
Surmodics, Inc.
42.98
+0.35%
4.2
Sell
Buy
Surmodics, Inc.
CERS
Cerus Corporation
3.12
-0.95%
8.2
Sell
Buy
Cerus Corporation
TCMD
Tactile Systems Technology, Inc.
28.43
+0.14%
6.7
Sell
Buy
Tactile Systems Technology, Inc.
ZIMV
ZimVie Inc.
18.99
+0.00%
5.1
Sell
Buy
ZimVie Inc.
KIDS
OrthoPediatrics Corp.
19.49
-0.15%
6.4
Sell
Buy
OrthoPediatrics Corp.

Events and news impacting Cytek Biosciences, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Cytek Biosciences, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.